BioMarin Pharmaceutical Inc. (BMRN)
Automate Your Wheel Strategy on BMRN
With Tiblio's Option Bot, you can configure your own wheel strategy including BMRN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMRN
- Rev/Share 15.3836
- Book/Share 30.3375
- PB 1.9069
- Debt/Equity 0.1028
- CurrentRatio 5.5203
- ROIC 0.0718
- MktCap 11094241600.0
- FreeCF/Share 3.2476
- PFCF 17.8887
- PE 21.0876
- Debt/Assets 0.0833
- DivYield 0
- ROE 0.0946
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | BMRN | Morgan Stanley | -- | Overweight | -- | $97 | July 3, 2025 |
| Upgrade | BMRN | Oppenheimer | Perform | Outperform | -- | $98 | Feb. 24, 2025 |
| Resumed | BMRN | Raymond James | -- | Outperform | -- | $79 | Oct. 10, 2024 |
| Upgrade | BMRN | Bernstein | Market Perform | Outperform | $94 | $110 | Aug. 20, 2024 |
News
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 70.8% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
Published: June 05, 2025 by: The Motley Fool
Sentiment: Positive
It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high.
Read More
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
Read More
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif.
Read More
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral
New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of comorbidities, surgeries and overall doctor visits SAN RAFAEL, Calif. , May 12, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from studies of VOXZOGO ® (vosoritide), demonstrating meaningful impact on tibial bowing in children with achondroplasia and investigational early efficacy results in other skeletal conditions.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
BioMarin's First-Quarter Earnings & Sales Beat Estimates
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
Published: April 17, 2025 by: PRNewsWire
Sentiment: Neutral
SAN RAFAEL, Calif. , April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m.
Read More
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read More
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Read More
What Makes BioMarin (BMRN) a New Buy Stock
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
Read More
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
About BioMarin Pharmaceutical Inc. (BMRN)
- IPO Date 1999-07-26
- Website https://www.biomarin.com
- Industry Biotechnology
- CEO Alexander Hardy
- Employees 3040